AB233693

Anti-VEGF Receptor 2 antibody [EPR21884-236]

20ul selling size
RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(8 Publications)

Rabbit Recombinant Monoclonal VEGF Receptor 2 antibody. Suitable for Flow Cyt, I-ELISA, ICC/IF and reacts with Mouse, Recombinant full length protein - Mouse samples. Cited in 8 publications.

View Alternative Names

CD309, Flk-1, Flk1, Kdr, Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, Kinase NYK, Protein-tyrosine kinase receptor flk-1, FLK-1

5 Images

Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Flow Cyt

Supplier Data

Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Flow cytometric analysis of bEnd.3 (mouse brain endothelioma cell line) cell line treated with 1 μg/ml Brefeldin A for 3 hours (red) and an untreated control (green) labeling VEGF Receptor 2 with ab233693 at 1/500 dilution treated with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.

BFA treatment reduced cell surface VEGF Receptor 2 [PMID : 21063020].

Gated on viable cells.

Flow Cyt

Supplier Data

Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Flow cytometric analysis of bEnd.3 (mouse brain endothelioma cell line, right) and NIH/3T3 (mouse embryo fibroblast cell line, left) cell line labeling VEGF Receptor 2 with ab233693 at 1/500 dilution compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) at 1/2000 dilution was used as the secondary antibody.

Gated on viable cells.

Negative control : NIH/3T3 [PMID : 20978347].

Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized bEnd.3 (mouse brain endothelioma) cells labeling VEGF Receptor 2 with ab233693 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Redistribution of the VEGF Receptor 2 from the perinuclear Golgi to vesicular structures throughout the cytosol after treatment with Brefeldin A (1 μg/ml, 3 hours) in bEnd.3. BFA treatment alters the subcellular localisation of VEGF Receptor 2 [PMID : 21063020].

The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor^® 594) (ab195889) (red) at 1/200 dilution.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) secondary antibody at 1/1000 dilution.

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized bEnd.3 (mouse brain endothelioma cell line) and NIH/3T3 (mouse embryo fibroblast cell line) cells labeling VEGF Receptor 2 with ab233693 at 1/1000 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing perinuclear staining in bEnd.3 cells.

Negative control : NIH/3T3 [PMID : 20978347].

The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor^® 594) (ab195889) (red) at 1/200 dilution.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor^® 488) (ab150077) secondary antibody at 1/1000 dilution.

Indirect ELISA - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

I-ELISA

Supplier Data

Indirect ELISA - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

ELISA analysis of Mouse VEGF R2 recombinant protein at 1000 ng/mL with ab233693. An Alkaline Phosphatase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) at 1/2500 dilution was used as the secondary antibody.

Carrier free

Anti-VEGF Receptor 2 antibody [EPR21884-236] - BSA and Azide free
665 Alexa Fluor® 647

Alexa Fluor® 647 Anti-VEGF Receptor 2 antibody [EPR21884-236]
519 Alexa Fluor® 488

Alexa Fluor® 488 Anti-VEGF Receptor 2 antibody [EPR21884-236]
578 PE

PE Anti-VEGF Receptor 2 antibody [EPR21884-236]

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR21884-236

Isotype

IgG

Carrier free

Reacts with

Mouse

Applications

I-ELISA, ICC/IF, Flow Cyt

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "IELISA" : {"fullname" : "Indirect ELISA", "shortname":"I-ELISA"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "IELISA-species-checked": "notRecommended", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Mouse": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/500", "FlowCyt-species-notes": "", "IELISA-species-checked": "guaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/1000", "ICCIF-species-notes": "" }, "Recombinant full length protein - Mouse": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "IELISA-species-checked": "testedAndGuaranteed", "IELISA-species-dilution-info": "", "IELISA-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

VEGF Receptor 2 also known as KDR or Flk-1 is a receptor tyrosine kinase important for mediating the effects of vascular endothelial growth factor (VEGF). This protein has a mass of approximately 150 kDa. It mostly expresses in vascular endothelial cells playing a primary role in the formation of blood vessels. The receptor can also be found in various non-endothelial tissues though in smaller amounts indicating its broad functional roles outside of the vascular system.

Biological function summary

VEGF Receptor 2 is important for angiogenesis and vascular permeability. It is part of the VEGF receptor family which also includes VEGF Receptors 1 and 3 forming a complex interaction network. Upon binding with VEGF it phosphorylates key proteins to initiate signals that regulate endothelial cell migration proliferation and survival. The receptor's function is critical for normal developmental processes and wound healing as well.

Pathways

VEGF Receptor 2 is especially important within the angiogenesis and vascular permeability pathways. It plays a central role in the VEGF signaling pathway alongside proteins like VEGF A which is the primary ligand for the receptor. The signaling through this receptor modulates various downstream proteins through phosphorylation linking it to pathways that control cellular responses essential for blood vessel formation and maintenance.

VEGF Receptor 2 is significantly linked with cancer and age-related macular degeneration. In the context of cancer the overexpression or dysregulation of VEGF and its receptors including VEGF Receptor 2 often leads to enhanced tumor angiogenesis promoting tumor growth and metastasis. Additionally the receptor interacts with other proteins in pathological states such as CD309 in endothelial cell-based assays which are used for research like flow cytometry and ELISA to monitor VEGF Receptor 2 activity and its impact on diseases.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as a negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and by preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

See full target information Kdr

style

left-column

Publications (8)

Recent publications for all applications. Explore the full list and refine your search

Neuroreport 36:350-363 PubMed40203233

2025

Long noncoding RNA MALAT1 promotes angiogenesis through the caveolin-1/VEGF pathway after cerebral ischemic injury.

Applications

Unspecified application

Species

Unspecified reactive species

Yao Lin,Qiongyi Pang,Yuanxi Shi,Xiang Chen,Fengxia Tu

Journal of extracellular vesicles 13:e12440 PubMed38659349

2024

Exhaled breath condensate contains extracellular vesicles (EVs) that carry miRNA cargos of lung tissue origin that can be selectively purified and analyzed.

Applications

Unspecified application

Species

Unspecified reactive species

Megan I Mitchell,Iddo Z Ben-Dov,Kenny Ye,Christina Liu,Miao Shi,Ali Sadoughi,Chirag Shah,Taha Siddiqui,Aham Okorozo,Martin Gutierrez,Rashmi Unawane,Lisa Biamonte,Kaushal Parikh,Simon Spivack,Olivier Loudig

Cellular & molecular biology letters 29:24 PubMed38317065

2024

The direct binding of bioactive peptide Andersonin-W1 to TLR4 expedites the healing of diabetic skin wounds.

Applications

Unspecified application

Species

Unspecified reactive species

Chao Li,Yuxin Xiong,Zhe Fu,Yuxin Ji,Jiayi Yan,Yan Kong,Ying Peng,Zeqiong Ru,Yubing Huang,Yilin Li,Ying Yang,Li He,Jing Tang,Ying Wang,Xinwang Yang

eLife 12: PubMed36719173

2023

Pericytes control vascular stability and auditory spiral ganglion neuron survival.

Applications

Unspecified application

Species

Unspecified reactive species

Yunpei Zhang,Lingling Neng,Kushal Sharma,Zhiqiang Hou,Anatasiya Johnson,Junha Song,Alain Dabdoub,Xiaorui Shi

The journal of gene medicine 25:e3462 PubMed36346049

2022

lncRNA ANRIL accelerates wound healing in diabetic foot ulcers via modulating HIF1A/VEGFA signaling through interacting with FUS.

Applications

Unspecified application

Species

Unspecified reactive species

Jia Wan,Yan Bao,Li-Juan Hou,Guo-Jian Li,Ling-Juan Du,Zhen-Huan Ma,Guo-Kai Yang,Yi Hou,Zhao-Xiang Li,Yong Yang

Ginekologia polska : PubMed35942721

2022

LncRNA-loc391533 is involved in the progression of preeclampsia through VEGF.

Applications

Unspecified application

Species

Unspecified reactive species

Jun Xiong,Xuan Jin,Kangxiang Xu,Bingqi Wu,Yuqi Xu,Dong Ruan,Xiaoju He

Cell proliferation 54:e13041 PubMed33942933

2021

Therapeutic effects of CXCR4 subpopulation of transgene-free induced cardiosphere-derived cells on experimental myocardial infarction.

Applications

Unspecified application

Species

Unspecified reactive species

Jianyong Xu,Huimei Wu,Zhigang Mai,Junbo Yi,Xianqi Wang,Lingyun Li,Zhong Huang

Cancer chemotherapy and pharmacology 87:125-134 PubMed33141330

2020

MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Long Yang,Zheyue Yuan,Yamin Zhang,Zilin Cui,Yang Li,Jiancun Hou,Xiaolong Liu,Zirong Liu,Rui Shi,Qing Tian,Jian Wang,Lianjiang Wang

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-VEGF Receptor 2 antibody [EPR21884-236]

Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Flow Cytometry - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Immunocytochemistry/ Immunofluorescence - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Indirect ELISA - Anti-VEGF Receptor 2 antibody [EPR21884-236] (AB233693)

Related conjugates and formulations (4)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (8)

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Product promise